Findings

What do systematic reviews say?

5 questions · 7 findings · 2 reviews · Epilepsy

No studies found 2 · 28.6%GRADE not reported 2 · 28.6%Very low 0 · 0%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%

Seizure freedom · participants with epilepsy (GTCS)

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 146 participants
GRADE not reported

Seizure freedom · people with epilepsy

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 100 participants
GRADE not reported

Seizure freedom · participants with epilepsy (BECTS)

Sulthiame showed no clear difference in seizure freedom compared with levetiracetam (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 1.12 [0.88, 1.44]
1 study · 43 participants
Low

Seizure freedom · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma

The review found no eligible studies for this question.

2 findings from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Seizure freedom · people with focal or generalized seizures

Clobazam showed no clear difference in seizure freedom at 4 weeks compared with carbamazepine (low certainty).

2 findings from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 0.85 [0.55, 1.32]
1 study · 43 participants
Low
Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 0.95 [0.66, 1.36]
1 study · 43 participants
Low